纤维化
硬皮病(真菌)
医学
整合素
免疫学
癌症研究
受体
内科学
接种
作者
Andrew Leask,Asmaa Fadl,Angha Naik
标识
DOI:10.1080/13543784.2024.2323528
摘要
INTRODUCTION: The potent profibrotic cytokine transforming growth factor-β (TGF-β) has been associated with the onset and progression of the fibrosis seen in the autoimmune connective tissue disease scleroderma (systemic sclerosis, SSc). AREA COVERED: This review explores the data supporting the notion that TGF-β contributes to SSc fibrosis and examines why initiating clinical trials in SSc aimed at targeting integrin-mediated latent TGF-β activation is timely. EXPERT OPINION: Targeting TGF-β directly has not been proven to be clinically effective in this disease. Conversely, targeting matrix stiffness, which perpetuates fibrosis, may have more promise. Intriguingly, targeting integrin-mediated activation of latent TGF-β, which bridges these concepts, may have therapeutic value.
科研通智能强力驱动
Strongly Powered by AbleSci AI